This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Enlightening The Jungle: The German Rules on Advertising Pharmaceuticals

Abstract

The legal rules applying to advertising medicines in Germany resemble a jungle. While a Medical Products Advertising Act (hereafter the Act) has been put in place, which concentrates on rules regarding advertising pharmaceuticals, the Act does not show the entire picture. It is surrounded and complemented by provisions embedded in other sources of law. Moreover, the legal structure of the Act is complex as the distinction between rules on advertising to professional parties and rules on marketing to end consumers is not clear in the face of the structure of the Act. Finally, provisions set out in the Act are of course subject to interpretation by competent courts, including both domestic ones and the European Court of Justice. Recently, courts have increasingly been making decisions which, have a significant impact upon how to construe and apply key rules and legal concepts of the Act. This essay strives to outline the chief categories in the light of pertinent case law, focussing on recent case law and taking both the Act and complementing other sources of law into account – thereby hopefully enlightening “the legal jungle” to some extent.

Author

Thorsten Witt
Corporate Counsel, Celesio, Germany

Biography: 1972: Born near Stuttgart (GER) 1992 - 1997: Studied law at universities of Tübingen (GER) and Leiden (NL) 1998: First German state exam and diploma of laws (Hons) 1998 - 2000: Legal trainee at law firms, courts and government authorities 2000: Second German state exam 2000: Admitted to the Stuttgart bar as a registered German lawyer (Rechtsanwalt) 2000 - today: Corporate Counsel in the central legal department of Celesio AG. Responsible for IP matters 2008: Examination as a certified IP lawyer (Fachanwalt für Gewerblichen Rechtsschutz)

Company

Celesio

Celesio, one of Europe's leading trading companies and service providers for pharmaceuticals, generated 22.3 billion Euro revenue in 2007. As of 30 September 2008, the group employed 37.811 people in 14 countries. The three business divisions Pharmacy Solutions, Patient and Consumer Solutions and Manufacturer Solutions cover the entire spectrum of pharmaceutical distribution and related services. 121 wholesale branches, which are part of Pharmacy Solutions, supply over 35.000 pharmacies in twelve countries in Europe daily. Celesio's 2.332 pharmacies are part of Patient and Consumer Solutions and each day serve more than 500.000 customers in seven countries. The Manufacturer Solutions division offers pharmaceutical manufacturers logistics and transportation services and supports them with sales and marketing.

Related Papers

Supported Studies Quid Pro Quo
Many pharmaceutical companies (hereinafter Companies or Company) recognize the importance of supporting external studies and the role they play in fulfilling patients’ needs. High standard ethical research conducted by external...Read more
Portrait image of Ann Turi
Ann Turi
Senior Legal Counsel, Legal and Compliance R&D and Medical Legal Team, Gsk, USA
US and International Codes on Pharmaceutical Marketing Practices and Interaction with Healthcare Professionals - A Comparative Analysis and Outlook on Harmonization by FCPA Enforcement
In recent years, there has been an increasing focus on pharmaceutical marketing practices and interactions between pharmaceutical companies and healthcare professionals.  Concerns about real and perceived improprieties have led to...Read more
Portrait image of Roy Birnbaum
Roy Birnbaum
Counsel, Human Health International, Merck & Co, Inc., USA
Pharmaceutical Advertising in Denmark - Where did Freedom of Expression go?
Differences in the legal approach to advertisement of pharmaceuticals still exist within the European Union even though Directive 2001/83/EC of the European Parliament and of the Council of 6 November...Read more
Portrait image of Nicolai Ellehuus
Nicolai Ellehuus
Attorney-at-Law, Novo Nordisk Inc, USA
Patent Strategies for Attenuated Pathogen Vaccines
Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more
Portrait image of David Dolberg
David Dolberg
Senior Director of Intellectual Property, Sanaria Inc., USA